A Closer Look at 7 Analyst Recommendations For NovoCure
A Closer Look at 7 Analyst Recommendations For NovoCure
對Novocure的7個分析師建議進行更深入的研究
7 analysts have shared their evaluations of NovoCure (NASDAQ:NVCR) during the recent three months, expressing a mix of bullish and bearish perspectives.
最近三個月，有7位分析師對NovoCure（納斯達克股票代碼：NVCR）進行了評估，表達了看好和看淡的觀點。
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
下表總結了他們最近的評級，展示了過去30天內不斷變化的情緒，並將其與前幾個月進行了比較。
Analysts have recently evaluated NovoCure and provided 12-month price targets. The average target is $25.29, accompanied by a high estimate of $42.00 and a low estimate of $17.00. This current average has decreased by 3.36% from the previous average price target of $26.17.
分析師最近對NovoCure進行了評估，並提供了爲期12個月的目標股價。平均目標價格爲25.29美元，高估值爲42.00美元，低估值爲17.00美元。這個當前的平均目標價格比之前的26.17美元的平均目標價格下降了3.36％。
Deciphering Analyst Ratings: An In-Depth Analysis
分析師評級解讀：深入分析
A comprehensive examination of how financial experts perceive NovoCure is derived...
對綜合了近期分析師行動...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。